PTC Therapeutics (PTCT) Misses Q3 EPS by 97c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to PTC Therapeutics (PTCT) Misses Q3 EPS by 97c, Revenues Beat

PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

October 29, 2020 4:01 PM EDT

SOUTH PLAINFIELD, N.J., Oct. 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the third quarter ending September 30, 2020 and provided a corporate update.

"I am very pleased by the rapid progress that we have made this quarter with the approval and strong U.S. launch of Evrysdi for spinal muscular atrophy and the continued growth across our global Duchenne muscular dystrophy franchise," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We have also made significant advances across our clinical pipeline with a... More